While alterations in oxytocin stimulatory proteins, oxytocin plasma levels and genetic variance in oxytocin receptors have been reported as risk factors for autism (Jacobson et al., 2014; LoParo and Waldman, 2015), clinical trials on the efficacy of oxytocin therapy has found only modest benefits or no positive effects (Young and Barrett, 2015). The gene discussed is OXT; the disease is autism.